Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Identifying HCV genotype 1 patients at risk of relapse.

DeschĂȘnes M, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Usaty C, Balshaw R, Peltekian KM; Canadian Pegasys Study Group.

Eur J Gastroenterol Hepatol. 2010 May;22(5):546-51. doi: 10.1097/MEG.0b013e32832d237d.


Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians.

Cooper CL, Bailey RJ, Bain VG, Anderson F, Yoshida EM, Krajden M, Marotta P; Canadian Pegasys Study Group.

Can J Gastroenterol. 2008 Aug;22(8):677-80.


Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.

Bain VG, Lee SS, Peltekian K, Yoshida EM, DeschĂȘnes M, Sherman M, Bailey R, Witt-Sullivan H, Balshaw R, Krajden M; Canadian PEGASYS Study Group.

Aliment Pharmacol Ther. 2008 Jul;28(1):43-50. doi: 10.1111/j.1365-2036.2008.03705.x. Epub 2008 Apr 7.


Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.

Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM; Canadian Pegasys Study Group.

J Viral Hepat. 2008 Jan;15(1):52-7.


Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.

Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS; Canadian Pegasys Study Group.

Gut. 2006 Nov;55(11):1631-8. Epub 2006 May 18.


Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.

Lee SS, Bain VG, Peltekian K, Krajden M, Yoshida EM, Deschenes M, Heathcote J, Bailey RJ, Simonyi S, Sherman M; CANADIAN PEGASYS STUDY GROUP.

Aliment Pharmacol Ther. 2006 Feb 1;23(3):397-408. Erratum in: Aliment Pharmacol Ther. 2006 Apr 1;23(7):1029.

Supplemental Content

Loading ...
Support Center